Osimertinib Cancer Treatment

Lord Bruce of Bennachie Excerpts

Tuesday 18th May 2021 Lords Chamber

[Lord Bethell (Con)]

My Lords, I have met with industry on this matter for the past 18 months. I am afraid that the message I get from it is not of the alarmist kind that the noble Lord described—quite the opposite. I pay tribute to the industry for its enormously collaborative sense of partnership and I really do not believe that there is any threat of the kind that the noble Lord described.

[Lord Bruce of Bennachie (LD) [V]]

Speaking from Aberdeenshire, I know that drug approval can differ between Scotland and England. Now that we have left the EU, is it not inevitable that there will be differences in drug approval and timings from time to time? What are the Government doing, having signed the agreement, to opt out of the EMA and negotiate an arrangement that minimises disruption but does not pretend that it cannot happen because that is what they signed up for?

[Lord Bethell (Con)]

My Lords, there will be an occasional moment when there are slight differences between the EMA and MHRA; we are not anticipating them to be huge and, in this case, we are anticipating them to be a matter of weeks while one approval does not quite overlap with another. The UK Government and the MHRA are working closely with the Northern Ireland Executive and all relevant stakeholders to ensure that the supply of medicines to all UK patients, including those in Northern Ireland, remains smooth, seamless and efficient.

Ebola

Lord Bruce of Bennachie Excerpts

Monday 13th October 2014 Commons Chamber

[Sir Malcolm Bruce (Gordon) (LD)]

The work that the British Government have done in Sierra Leone and Liberia to build health systems has been extremely important, but those systems were clearly inadequately developed to cope with this kind of problem. I welcome the joined-up thinking across government, but will the Secretary of State give me an assurance that the legacy of this situation will be not only that we have contained Ebola but that we have built health systems in those countries that are capable of dealing with future outbreaks? The long-term legacy must be stronger health systems, as well as the protection of British citizens, which is of course important.

[Mr Hunt]

I remember working with the right hon. Gentleman on the International Development Select Committee many years ago, when we had many conversations about strengthening the resilience of local health care systems. He is absolutely right to say that that must be our long-term goal, and I will ask the Secretary of State for International Development to write to him to explain how our efforts in Sierra Leone will help to strengthen its local health care system in the long run. The simple point I would make is that this illustrates the dual purpose of our aid budget more powerfully than any example I can remember. First, our aid budget gives humanitarian assistance to some of the poorest countries in the world and, secondly, it protects the population at home in the UK. Those two aims go hand in hand.